Exhibit 99.1

NEWS RELEASE
FOR IMMEDIATE RELEASE

VITAL SIGNS, INC. ANNOUNCES A 12.5% INCREASE IN
THIRD QUARTER EARNINGS FROM CONTINUING OPERATIONS,
EXTENDS FACE MASK AGREEMENT.

          TOTOWA, N.J., August 8, 2007 -- VITAL SIGNS, INC. (NASDAQ: VITL) today announced sales and earnings for the third quarter ended June 30, 2007.

          Income from continuing operations increased 12.5% to $8,733,000, for the third quarter of fiscal 2007 compared to $7,764,000 for the third quarter of fiscal 2006. Earnings from continuing operations per diluted share increased 12% to $.66 per share for the third quarter of fiscal 2007 compared to $.59 per share for the third quarter of fiscal 2006.

          Net revenues for the third quarter of fiscal 2007 increased 6.6% to $51,735,000 compared to $48,544,000 in the comparable period last year.

          Following are the net revenues by business segment for the third quarter of fiscal 2007 compared to the third quarter of fiscal 2006 (in thousands of dollars):

	NET REVENUES BY BUSINESS SEGMENT
	FOR THE THREE MONTHS ENDED
	JUNE 30,
	2007		2006		PERCENT
					CHANGE
Anesthesia	$	19,876	$	18,379	8.2	%
Respiratory/Critical Care		11,550		11,438	1.0	%
Sleep		13,352		11,973	11.5	%
Interventional cardiology/radiology		6,957		6,754	3.0	%
Net Revenues	$	51,735	$	48,544	6.6	%

          For the nine month period ended June 30, 2007 income from continuing operations increased 16.9% to $25,014,000 as compared to $21,390,000 for the comparable fiscal 2006 period. Diluted earnings per share from continuing operations increased 13.9% to $1.88 for the nine month period ended June 30, 2007 compared to $1.65 for the nine month period ended June 30, 2006.

          Net revenues for the first nine months of fiscal 2007 increased 6.3% to $147,790,000 as compared to $138,980,000 in the comparable period last year.

          Following are the net revenues by business segment for the nine months ended June 30, 2007 and 2006 (in thousands of dollars):

	NET REVENUES BY BUSINESS SEGMENT
	FOR THE NINE MONTHS ENDED JUNE 30,
					PERCENT
	2007		2006		CHANGE
Anesthesia	$	56,453	$	53,957	4.6	%
Respiratory/Critical Care		34,831		32,943	5.7	%
Sleep		36,710		33,780	8.7	%
Interventional cardiology/radiology		19,796		18,300	8.2	%
Net Revenues	$	147,790	$	138,980	6.3	%

          Terry Wall, President and CEO of Vital Signs commented “We introduced two new Anesthesia products in July: Pi’s Pillow™ and InfusaScan™. Pi’s Pillow™ is a head positioning device invented by a physician to help position the patient’s trachea for ease of intubation and increase patient comfort. InfusaScan™ is a new version of our market leading pressure infusor with a clear window that allows for bar code scanning as well as improved visibility of fluid levels.

          We have reduced our guidance to $2.55 -2.58 per share. This revision is primarily the result of slower adoption of our strategy of providing CPAP units to the patients diagnosed with obstructive sleep apnea through our sleep centers. We remain confident that we will be able to increase our distribution of CPAP devices to our patients over the next four quarters, targeting 50% market penetration.”

          On August 3, 2007, Vital Signs extended its exclusive supply agreement with Respironics for six months and purchased related mask manufacturing equipment for $1.5 million. Mr. Wall commented, “This agreement gives us additional supply chain protection as we transition the production of anesthesia face masks, avoids litigation regarding ownership of the tooling and clarifies a non-compete to protect our mask business. Previously discussed cost savings will now be realized in the third quarter of fiscal 2008.”

          On August 2, 2007 the Board approved a quarterly dividend to $0.10 per share payable on August 31, 2007 to shareholders of record on August 17, 2007.

          All non-historical statements in this press release, including Vital Signs’ guidance with respect to fully diluted earnings per share from continuing operations for fiscal 2007, constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of risks and uncertainties, including unanticipated delays in bringing products to market, regulatory approval of new products, market conditions, and competitive responses as well as other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2006.

          Vital Signs, Inc. and its subsidiaries design, manufacture and market primarily single-use medical products for the anesthesia, respiratory/critical care, achieving the number one market share position in the U.S. for five of its major product categories. Vital Signs also provides diagnostic services and therapeutic devices for the treatment of obstructive sleep apnea. Vital Signs is ISO 13485 certified and has CE Mark approval for its products. In 2006, Forbes Magazine named Vital Signs, Inc. as one of the “200 Best Small Companies in America” based on financial criteria.

VITL-G
FOR FURTHER INFORMATION, CONTACT:	Terry D. Wall, President
	or William Craig, CFO
	(973) 790-1330
	http://www.vital-signs.com

VITAL SIGNS, INC.
FINANCIAL HIGHLIGHTS
STATEMENT OF INCOME

(In Thousands, Except Per Share Amounts)
(Unaudited)

	THREE MONTHS ENDED						NINE MONTHS ENDED
	JUNE 30,						JUNE 30,
	2007			2006			2007			2006
Gross revenues	$	70,373		$	66,259		$	203,046		$	189,757
Rebates		(18,071	)		(16,629	)		(52,332	)		(47,466	)
Other deductions		(567	)		(1,086	)		(2,924	)		(3,311	)
Net revenues		51,735			48,544			147,790			138,980
Cost of goods sold and services provided		23,581			22,890			68,498			66,046
Gross Profit		28,154			25,654			79,292			72,934
Expenses:
Selling, general and administrative		13,638			12,301			38,265			36,384
Research and development		2,042			1,897			5,614			5,294
Restructuring charge		—			—			—			—
Interest and other (income)/expense, net		(1,074	)		(753	)		(2,853	)		(1,994	)
Income from continuing operations
Before income taxes and minority interest		13,548			12,209			38,266			33,250
Provision for income taxes		4,538			4,153			12,479			11,196
Income from continuing operations before
minority interest		9,010			8,056			25,787			22,054
Minority interest		277			292			773			664
Income from continuing operations		8,733			7,764			25,014			21,390
(Loss) Income from discontinued operations, net		( 108	)		180			(494	)		682
Net income	$	8,625		$	7,944		$	24,520		$	22,072
Earnings (loss) per common share:
Basic:
Income per share from continuing operations	$	0.66		$	0.59		$	1.89		$	1.66
Discontinued operations		( 0.01	)		0.01			( 0.04	)		0.05
Net earnings	$	0.65		$	0.60		$	1.85		$	1.71
Diluted:
Income per share from continuing operations	$	0.66		$	0.59		$	1.88		$	1.65
Discontinued operations		( 0.01	)		0.01			( 0.04	)		0.05
Net earnings	$	0.65		$	0.60		$	1.84		$	1.70
Basic weighted average number of shares		13,233			13,159			13,223			12,881
Diluted weighted average number of shares		13,274			13,208			13,272			12,962

VITAL SIGNS, INC.
FINANCIAL HIGHLIGHTS

BALANCE SHEET HIGHLIGHTS:

	(In Thousands)
	(Unaudited)
	June 30,
	2007		2006
Cash and cash equivalents	$	53,237	$	29,409
Short Term Investments		82,395		88,687
Accounts Receivable		37,729		29,934
Inventory		20,525		18,933
Current Assets		216,538		191,630
Total Assets	$	335,014	$	297,473
Current Liabilities	$	17,723	$	14,665
Total Liabilities		17,723		14,665
Shareholders equity	$	311,382	$	278,369